Helen Torley, M.B. Ch. B., M.R.C.P., has been appointed president and chief executive officer of Halozyme, and will serve on the board of directors. Dr. Torley most recently served as executive vice president and chief commercial officer at Onyx Pharmaceuticals, a subsidiary of Amgen. She replaces Gregory I. Frost, Ph.D., who is leaving the company to become head of Intrexon’s health sector. Dr. Frost will continue to lead Halozyme’s scientific advisory board. 
 
“Helen’s demonstrated leadership of Onyx’s oncology products will build on Halozyme’s trajectory of value creation, pivoting from partnered to proprietary products,” said Kenneth J. Kelley, chairman of the board of directors of Halozyme. “She brings more than 20 years of successful brand development and launch expertise garnered from key roles at other companies, including Amgen and Bristol-Myers Squibb.”
 
RJ Kirk, Halozyme’s largest shareholder and a member of the board, said, “Halozyme has successfully transitioned over the last several years from being science-driven to become commercially-oriented. This is a very fortunate position to be in for any company. I laud the efforts by Greg in leading the company to its present position with multiple product approvals under its belt. Halozyme’s advanced, proprietary products are game-changing for the company, and we must be prepared to maximize the realization of its commercial opportunities. Helen is an ideal choice to lead the company at this important moment in its trajectory.”